TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
AMRN

Amarin Corporation PLC

Healthcare · Drug Manufacturers - General

13.80$ -2.0% vs. previous close Closing price · As of: Aug 24, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Amarin Corporation PLC (AMRN). It shows which part of the business is growing — and which one is holding it back.

Revenue by product line

Revenue by product line — AMRN
Segment 2020 2021 2022 2023 2024 2025
Product Revenue, Net $607.0M 98.9% $580.3M 99.5% · -4.4% $366.5M 99.3% · -36.8% $285.3M 93.0% · -22.2% $204.6M 89.5% · -28.3% $182.8M 85.5% · -10.7%
Licensing and Royalty Revenue $7.0M 1.1% $2.9M 0.5% · -59.2% $2.7M 0.7% · -6.5% $21.6M 7.0% · +705.8% $24.0M 10.5% · +11.2% $30.9M 14.5% · +28.6%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?